Wilmington PharmaTech Announces Major Expansion to Strengthen U.S. API Manufacturing
Wilmington PharmaTech, a leading U.S.-based contract research, development, and manufacturing organization specializing in complex custom small-molecule active pharmaceutical ingredient production, has announced a significant $50 million expansion of its Delaware campus aimed at more than doubling its current API reactor capacity, reinforcing its commitment to meeting the rapidly growing demand for high-quality, domestically manufactured pharmaceutical ingredients and strengthening the United States’ position in global pharmaceutical supply chains
Increasing Capacity with Advanced Reactor Infrastructure
The expansion project will include the addition of two new 10,000-liter reactor suites, representing a substantial enhancement of Wilmington’s commercial-scale manufacturing capabilities and enabling the company to support large-scale production requirements for both small molecule APIs and peptide-based therapies, while also improving operational flexibility and efficiency for handling complex chemistry processes that require precise control and scalability across different stages of drug development and commercialization
Timeline and Workforce Growth Projections
The newly planned reactor suites are expected to become operational in the third quarter of 2027, marking a key milestone in Wilmington’s long-term growth strategy, and upon completion of the expansion, the company anticipates a significant increase in its workforce at the Delaware site, with projections indicating that the number of employees will approximately double, reflecting the increased operational capacity and the need for additional skilled professionals to support expanded manufacturing activities and ensure continued compliance with stringent regulatory standards
Strategic Investment in Domestic Manufacturing
This latest investment represents the second phase of Wilmington’s broader multi-year initiative to expand domestic API manufacturing capacity within the United States, highlighting the company’s proactive approach to addressing industry challenges related to supply chain security and resilience, and by increasing local production capabilities, Wilmington aims to reduce reliance on overseas manufacturing while providing biopharmaceutical companies with a reliable and secure domestic partner for their API production needs
Building on High-Potency API Capabilities
The expansion builds upon Wilmington’s recent investments in dedicated manufacturing suites for highly potent active pharmaceutical ingredients, which are critical for the development of advanced therapies requiring precise handling and specialized containment systems, and by integrating these high-potency capabilities with expanded large-scale production infrastructure, the company is creating a comprehensive manufacturing platform that can support a wide range of pharmaceutical applications, from early-stage development to full commercial production
Leadership Perspective on Growth and Innovation
According to Hui-Yin Harry Li, Founder and Chief Executive Officer of Wilmington PharmaTech, the company has been among a select group of organizations that have consistently invested in current Good Manufacturing Practice API manufacturing capacity within the United States over the past decade, and he emphasized that the new expansion builds on more than twenty years of expertise in cGMP manufacturing while further strengthening Wilmington’s ability to address complex chemistry challenges at scale through a high-output scientific and operational framework
Supporting Biopharmaceutical Innovation
The expansion is expected to play a crucial role in supporting biopharmaceutical innovators who require scalable and reliable manufacturing solutions for their drug development programs, particularly as the industry continues to evolve toward more complex and specialized therapies, and by offering enhanced capacity and advanced technological capabilities, Wilmington aims to provide its partners with the tools and infrastructure needed to accelerate the development and commercialization of new treatments while maintaining high standards of quality and regulatory compliance
Backing from Strategic Investment Partners
Curewell Capital, a key investment partner supporting Wilmington PharmaTech, has expressed strong confidence in the company’s growth strategy and its ability to deliver high-quality commercial API production within the United States, with Kent Payne, Operating Partner at Curewell Capital and Managing Director at Wilmington PharmaTech, noting that the company is uniquely positioned to serve biopharmaceutical innovators by providing reliable and scalable domestic production capabilities that enhance supply chain resilience and help ensure patient access to critical therapies
Strengthening Supply Chain Resilience
In an era where global supply chain disruptions have highlighted the importance of domestic manufacturing capabilities, Wilmington’s expansion represents a strategic effort to strengthen the resilience of pharmaceutical supply chains within the United States, and by increasing local production capacity for APIs, the company is helping to mitigate risks associated with international dependencies while supporting the broader goal of ensuring a stable and secure supply of essential medicines for patients
State-of-the-Art Facilities in Delaware
Headquartered in Newark, Delaware, Wilmington PharmaTech operates on a 54-acre campus that includes two adjacent state-of-the-art manufacturing facilities equipped with extensive cGMP capabilities, and these facilities are designed to support a wide range of production activities, from small-scale clinical manufacturing to large-scale commercial operations, providing the flexibility needed to accommodate diverse customer requirements and evolving industry demands
Comprehensive API Development and Manufacturing Services
Wilmington PharmaTech offers a full spectrum of services covering the entire lifecycle of small molecule API development and manufacturing, leveraging deep scientific expertise gained through hundreds of drug substance programs and more than 200 investigational new drug submissions, and its integrated approach combines the capabilities of a contract research organization with those of a contract development and manufacturing organization, enabling seamless transitions from early-stage discovery through clinical development and into commercial production
Integrated Solutions for Complex Drug Development
The company’s service offerings include custom synthesis, medicinal chemistry support, process development, analytical testing, starting material supply, and large-scale cGMP manufacturing, all delivered through a coordinated and efficient framework that minimizes delays and enhances overall project execution, and this integrated model allows Wilmington to address complex drug development challenges while providing clients with a single, reliable partner for their API needs
Global Presence Supporting Innovation
In addition to its U.S.-based operations, Wilmington PharmaTech maintains an accelerated development and analytical support facility in Suzhou, China, which complements its domestic manufacturing capabilities by providing additional resources for research and development activities, enabling the company to support global clients with a combination of localized production and international expertise that enhances efficiency and innovation across its service offerings
Enabling Scalable and Future-Ready Manufacturing
Through its ongoing investments in infrastructure, technology, and talent, Wilmington PharmaTech is positioning itself as a leader in scalable and future-ready API manufacturing, capable of meeting the evolving needs of the pharmaceutical industry while maintaining a strong focus on quality, efficiency, and innovation, and the latest expansion in Delaware underscores the company’s commitment to driving growth and delivering value to its customers by providing reliable, high-performance manufacturing solutions within the United States
Advancing the Future of Pharmaceutical Manufacturing
As demand for complex and high-quality pharmaceutical ingredients continues to grow, Wilmington PharmaTech’s expansion represents a significant step forward in enhancing domestic manufacturing capabilities and supporting the development of innovative therapies, and by combining advanced infrastructure with deep scientific expertise and a customer-centric approach, the company is well-positioned to play a key role in shaping the future of pharmaceutical manufacturing while contributing to improved healthcare outcomes worldwide
Source link:https://www.businesswire.com/
